Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. (Q30370326)

21 June 2017

1 reference

title

Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. (English)

1 reference

21 June 2017

0 references

Leslie Citrome

1

0 references

author name string

Joshua Kantrowitz

series ordinal

2

1 reference

21 June 2017

publication date

1 July 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

21 June 2017

published in

1 reference

21 June 2017

volume

8

1 reference

21 June 2017

issue

7

1 reference

21 June 2017

page(s)

1079-1091

1 reference

Atypical antipsychotics for acute agitation. New intramuscular options offer advantages.

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Remission in schizophrenia: proposed criteria and rationale for consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Recovery and systems transformation for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Size of treatment effects and their importance to clinical research and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Evidence-based medicine and psychiatric practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Compelling or irrelevant? Using number needed to treat can help decide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Show me the evidence: using number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Rethinking antipsychotic formulary policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Glutamate as a therapeutic target in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Pathophysiologically based treatment interventions in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Olanzapine: interpreting the label change

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Medication-induced hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Sexuality and schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Diabetes, psychological function and male sexuality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

An excitement subscale of the Positive and Negative Syndrome Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

21 January 2018

Paliperidone: quo vadis?

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Dose response and dose equivalence of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Pharmacogenetics of antipsychotics: useful for the clinician?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

Dosing of Second-Generation Antipsychotic Medication in a State Hospital System

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1079

10.1586/14737175.8.7.1079

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference